Nafazatrom
| Code | Size | Price |
|---|
| TAR-T33579-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T33579-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T33579-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacyclin levels and reduces the incidence of arrhythmias associated with cardiac injury.
CAS:
59040-30-1
Formula:
C16H16N2O2
Molecular Weight:
268.316
Purity:
0.98
SMILES:
CC1=NN(CCOc2ccc3ccccc3c2)C(=O)C1
References
Gillis CN, Havill AM, Moalli R. Effect of nafazatrom and indomethacin on pulmonary removal of prostaglandin E1 after endotoxin in rabbits. Br J Pharmacol. 1987 Aug;91(4):721-8. PubMed PMID: 3311263; PubMed Central PMCID: PMC1853588.
Jones AL, Powles TJ, Forgeson GV, Coombes RC. A clinical study of nafazatrom in advanced human breast cancer. Cancer Chemother Pharmacol. 1991;27(4):326-8. PubMed PMID: 1998990.
Massad L, Plotkine M, Boulu RG. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine. Thromb Res. 1988 Jun 1;50(5):617-25. PubMed PMID: 3137682.
Bj?ro T, Larsen V, Englund K, Torjesen PA, Haug E. The lipoxygenase inhibitor nafazatrom inhibits stimulated prolactin secretion in cultured rat lactotrophs (GH4C1 cells). Scand J Clin Lab Invest. 1992 Jun;52(4):297-303. PubMed PMID: 1332181.